Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alvin Ngan

Podiatrist Seattle, WA Doctor of Podiatric Medicine

NPI 1245448935 CMS profile 147761

1100 9Th Ave, Seattle, WA 98101

Open in the dashboard

General payments

$13,468

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alvin Ngan of Seattle, WA is reported in the CMS Open Payments database as having received $13,468 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,703 22
2024 General $2,458 12
2023 General $911 8
2022 General $4,010 12
2021 General $1,486 4
2020 General $149 1
2019 General $1,753 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alvin Ngan
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Alvin Ngan were reported at $2,703. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Alvin Ngan Podiatrist median Middle half National median
2019 $1,753 $196 $72–$601 $163
2020 $149 $118 $38–$335 $114
2021 $1,486 $169 $57–$573 $132
2022 $4,010 $220 $74–$782 $149
2023 $911 $208 $71–$635 $160
2024 $2,458 $237 $87–$681 $164
2025 $2,703 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Summit Surgical Corp. $3,699 4 payments
  2. Paragon 28, Inc. $3,358 14 payments
  3. Stryker Corporation $1,621 13 payments
  4. Orthofix Medical, Inc. $1,380 14 payments
  5. Medical Device Business Services, Inc. $726 4 payments
  6. Wright Medical Technology, Inc. $720 7 payments
  7. AxoGen $342 3 payments
  8. DePuy Synthes Sales Inc. $331 5 payments
  9. Exactech, Inc. $196 1 payment
  10. Kerecis Limited $168 1 payment
  11. Other $928 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,032 17 payments
  2. Food and Beverage $4,836 58 payments
  3. Education $3,600 3 payments
Products named General payments · program years 2019–2025
  1. MONKEY RINGS $1,153 4 payments
  2. INFINITY $941 3 payments
  3. TL-HEX $927 10 payments
  4. TrueLok Ring Fixation System $927 10 payments
  5. MOTOBAND $770 5 payments
  6. PRODUCT PORTFOLIO $567 1 payment
  7. APEX 3D $457 2 payments
  8. PORTFOLIO $454 1 payment
  9. APEX $358 2 payments
  10. Avance Nerve Graft $342 3 payments
  11. Other $5,262 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

37

Median for Podiatry: 160

Drug cost

$219

Median for Podiatry: $2,368

Branded share of claims

32.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 25 $129
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $90

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$33,556

Of which drugs: $19

Medicare patients

179

Average age 74

Services billed

438

111 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 55%
Ischemic heart disease 16%
Cancer 16%
Depression 16%
Osteoporosis 16%
Diabetes 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 74 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record